Lakefront Biotherapeutics NV
32.28USD
-0.0500 (-0.15%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LKFT.
Valuation
P/E (TTM)
3.57x
P/E (Forward)
—
EV/EBITDA
72.05x
EV/Revenue
40.54x
P/S (TTM)
2.15x
P/B
0.65x
FCF Yield
-10.88%
Dividend Yield
0.00%
Gross Margin
97.45%
Operating Margin
61.57%
Net Margin
60.23%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| LKFTLakefront Biotherapeutics NV | $2.13B | 3.57x | 72.05x | -10.88% | -81.45% | 0.00% |
| VRTXVertex Pharmaceuticals Incorporated | $141.56B | 32.55x | 26.63x | 1.86% | 12.50% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $95.53B |
| 22.94x |
| 18.59x |
| 3.21% |
| 16.70% |
| 0.46% |
| MRNAModerna, Inc. | $88.93B | — | — | 0.34% | 2.10% | 0.00% |
| ARGXargenx SE | $56.46B | 31.10x | 735.70x | — | 52.10% | 0.00% |
| RPRXRoyalty Pharma plc | $38.82B | 35.73x | 26.32x | -3.08% | 16.50% | 1.43% |
| ROIVRoivant Sciences Ltd. | $27.10B | — | — | -4.12% | -33.50% | 0.00% |
| INCYIncyte Corporation | $24.40B | 15.34x | 25.55x | — | 14.00% | 0.00% |
| BNTXBioNTech SE | $22.39B | — | — | -1.11% | -59.50% | 0.00% |